What is Glycomet?

Glycomet SR(Metformin) tablets are primarily prescribed for the effective management of type 2 diabetes mellitus. By assisting in regulating blood sugar levels, it plays a crucial role in preventing the onset of serious complications associated with diabetes.

Find out more about Glycomet SR

Glycomet SR 500/850/1000mg: Each uncoated tablet contains metformin hydrochloride IP (as sustained release) 500/850/1000mg.






Why Glycomet SR?

Metformin is the only pharmacologic agent recommended for the prevention or postponement of T2D. Metformin is the first line of treatment for prediabetes patients in appropriate cases to reduce the risk of type 2 diabetes progression.2
Metformin is indicated as monotherapy to lower blood glucose in patients with type 2 diabetes mellitus whose blood glucose cannot be satisfactorily managed on diet and exercise. It may be used concomitantly with a sulphonyl urea when diet and Metformin or a sulphonyl urea monotherapy do not result in adequate glycemic control.


Metformin effectively prevents diabetes, especially in younger individuals with higher body weights

Metformin supports glycemic hygiene, vascular hygiene, and vasculometabolic hygiene





Dosage

Metformin 500mg twice daily

RSSDI (India, 2020)4



Metformin 850mg twice daily

Diabetes prevention Program5




Available SKU

Sustained release SKUs
Immediate release SKUs

Approval and Recommendations

ADA

Metformin for preventing T2DM recommended for prediabetic individuals, especially with BMI ≥35 kg/m²,<60 years old, or with prior gestational diabetes4.

RSSDI

Metformin 500 mg, twice daily for overweight/obese individuals with IFG + IGT or IFG + HbA1c >5.7%5.

ICMR

For rapid progression from prediabetes to diabetes, metformin is considered alongside lifestyle changes, especially for those with combined IFG and IGT, particularly in high-risk groups2

ADA- American Diabetes Association, RSSDI- Research Society for the Study of Diabetes in India, ICMR- Indian Council of Medical Research.


References

1) Chawla R, Madhu SV, Makkar BM, et al. RSSDI-ESI clinical practice recommendations for the management of type 2diabetes mellitus 2020. Int J Diabetes Dev Ctries 2020;40(1):1–224. 2) Das AK, et.al An Expert Group Consensus Statement on "Approach and Management of Prediabetes in India". J Assoc Physicians India. 2022 Dec;70(12):11-12. doi: 10.5005/japi-11001-0162. PMID: 37355974. 3) Aroda VR, et al. Diabetologia. 2017; 60(9):1601-11 4) Aroda VR, Ratner RE. Metformin and Type 2 Diabetes Prevention. Diabetes Spectr. 2018 Nov;31(4):336-342. doi: 10.2337/ds18-0020. PMID: 30510389; PMCID: PMC6243218. 5) RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. Int J Diabetes Dev Ctries 42 (Suppl 1), 1–143 (2022). https://doi.org/10.1007/s13410-022-01129-5